Aktienanalyse zu Precipio Inc (PRPO)PRPOPrecipio Inc

Precipio, Inc. is a healthcare biotechnology company that is focused on cancer diagnostics. The Company’s technologies include HemeScreen and IV-Cell. The HemeScreen panels test for the presence of various mutations. In developing HemeScreen, it focused on improving the economics of providing blood cancer diagnostic tests and reducing laboratory technician time consumed in the testing process. Its technology enables testing to be completed in one rapid scanning process. IV-Cell is a cell culture media that addresses the problem of diagnostic mistakes through the process of selective culturing. IV-Cell is a universal media that enables simultaneous culturing of all four hematopoietic cell lineages. Its product category includes Molecular Kits and IV-Cell Cytogenetics Media. The Molecular Kits include Quantitative MPN Panel, ABL1 Resistance Panel, and others. The Company’s laboratory and research and development (R&D) facilities are located in New Haven, Connecticut and Omaha, Nebraska. It operates in the Healthcare sector (LABORATORY ANALYTICAL INSTRUMENTS industry).

Precipio Inc is not a good buy right now. The current price is $17.79, which is significantly below its 52-week high of $33.63, indicating a 47.58% decline. Additionally, the RSI is at a very low 18.41, suggesting the stock is oversold, but this could indicate ongoing weakness rather than a buying opportunity. The company has reported a net loss of $1.44 million in Q1 2026 and a negative net margin of -21.50%, raising concerns about its profitability and financial stability. The main risk is the declining revenue trend, with a 20-day change of -25.87%, which could further impact investor sentiment.

1 analysts cover PRPO: 1 rate it Buy, 0 Hold and 0 Sell.